AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01211418 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrative Meditation
Description: Stage 1: Treatment Engagement and Detoxification. Use 6 breaths/minute as near resonant-frequency.~Stage 2: Recovery and transition by reducing craving and irritability. Wk 3: introduce 16-mins IM. Wk 4: RFB \& IM as a coping tool. Wk 5: add guided imagery into IM. Wk 6: review and catch-up if miss any prior sections.~Stage 3: Revitalization and Relapse Prevention. Wk 7: customize guided imagery. Wk 8: introduce full version of IM. Wk 9: techniques of handling random thoughts during meditation and learn to separate thoughts from action. Wk 10: how to use IM techniques to handle different relapse triggers. Wk 11: different ways to integrate IM technique into daily life. Wk 12: review, feedback, and provide local sources for more meditation practice and study.
Study NCT01211418 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Counseling
Description: NT is a procedure in which the therapist refrains from directing the client, but instead reflects back to the client what the latter has said. NT is chosen for this study to control for non-specific effects that show to contribute to outcome such as therapeutic alliance and therapist competency.~The protocol for the individualized NT will mirror the layout of IM therapy -12 weekly meetings, 30 minutes each. Subjects in NT group will be instructed to do Diaphragmatic Breathing (DB) exercise and will be given assigned homework (writing journal) and track progress. DB is incorporated into the NT as treatment providing non-specific effects associated with attention and homework completion.
Study NCT02897986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of a propranolol (HEMANGIOL®) and oral metronomic vinorelbine (NAVELBINE®) combination
Study NCT03668236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotonic crystalloids
Description: Types of fluid to be used in both intervention groups:~* IV fluids given for circulatory impairment: Only isotonic crystalloids are to be used as per the Scandinavian guideline for fluid resuscitation~* Fluids given to substitute overt loss: Isotonic crystalloids are to be used. If large amounts of ascites are tapped, then human albumin may be used~* Fluids used for dehydration: Water or isotonic glucose should be used~* Fluids used for electrolyte disturbances: Fluids should be chosen to substitute the specific deficiency, including water in the case of severe hypernatremia~* Blood products are only to be used on specific indications including severe bleeding, severe anaemia and prophylactic in case of severe coagulopathy
Study NCT03668236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic crystalloids
Description: Types of fluid to be used in both intervention groups:~* IV fluids given for circulatory impairment: Only isotonic crystalloids are to be used as per the Scandinavian guideline for fluid resuscitation~* Fluids given to substitute overt loss: Isotonic crystalloids are to be used. If large amounts of ascites are tapped, then human albumin may be used~* Fluids used for dehydration: Water or isotonic glucose should be used~* Fluids used for electrolyte disturbances: Fluids should be chosen to substitute the specific deficiency, including water in the case of severe hypernatremia~* Blood products are only to be used on specific indications including severe bleeding, severe anaemia and prophylactic in case of severe coagulopathy
Study NCT01229735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: 250 mg and 500 mg levetiracetam tablet 1000 mg/day (500 mg bid) levetiracetam (maximum to 3000 mg/day) Duration: maximum 52 weeks
Study NCT01229735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate
Description: 25 mg and 100 mg topiramate tablet 100 mg/day(50 mg bid) topiramate (maximum to 400 mg/day) Duration: maximum 52 weeks
Study NCT02331368 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplant
Study NCT02331368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 140-200 mg/m\^2
Study NCT02331368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 5-15 mg/day starting 45-90 days post-transplant
Study NCT02331368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: 200 mg/day every 3 weeks starting day +14 post-transplant for a total of 9 doses.
Study NCT03912441 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-147
Description: Bispecific anti-HER2 monoclonal antibody
Study NCT02218125 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA Mosaic
Description: 0.5 mL (1x10E8 pfu) MVA Mosaic (comprised of MVA Mosaic 1 and MVA Mosaic 2 mixed in a 1:1 ratio before administration) will be administered by intramuscular (IM) injection.
Study NCT02218125 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL Sodium Chloride Injection USP, 0.9%will be administered by intramuscular (IM) injection.
Study NCT04481321 — intervention group
Intervention type: BIOLOGICAL
Intervention: Biological/Vaccine
Study NCT04596228 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-899
Description: Treatment with intensities of a magnetic field and radiofrequency energy just below the patient's tolerance threshold.
Study NCT01663935 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Levodopa/carbidopa
Description: This study will have an intent to treat goal. Anyone that fits the inclusion criteria for the study will be entered and receive study drug.
Study NCT04131153 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: radiofrequency ablation
Description: Conventional radiofrequency ablation
Study NCT03671252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI
Description: Irinotecan165 mg/m2、Oxaliplatin85 mg/m2、Left-calcium leucovorin 200mg/㎡，Intravenous infusion，first day. Then, 5-FU 1600 mg/m2/d×2 continuous intravenous infusion（total 3200 mg/m2，infusion 46 hours）in the next two days. Repeat every 14 days.
Study NCT03671252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELOX
Description: XELOX consisting of 130 mg/m2 oxaliplatin administered intravenously on day 1 and 1,000 mg/m2 capecitabine administered orally twice daily on days 1-14 for a 3-week cycle.
Study NCT02831647 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AYMES PRAGUE
Description: AYMES PRAGUE is a ready to drink, high energy, low volume oral nutritional supplement drink. It provides 300 kcal and 12g protein per 125ml serving. It is a Food for Special Medical Purposes (FSMP) and must therefore be used under medical supervision. It is not designed as a sole source of nutrition.
Study NCT01712737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Study NCT01041183 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous ramosetron
Description: 0.3 mg IV ramosetron (group I)
Study NCT03671252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: XELOX consisting of 130 mg/m2 oxaliplatin administered intravenously on day 1 and 1,000 mg/m2 capecitabine administered orally twice daily on days 1-14 for a 3-week cycle.
Study NCT03671252 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chemoradiotherapy
Description: Chemotherapy: oral capecitabine（1650 mg/m2）twice daily during radiotherapy without weekend breaks.~Radiation: Radiation therapy is administered via intensity-modulated radiation therapy (IMRT) with a linear accelerator, 6MV-X ray. The patients are scheduled to receive a GTV expanding 6mm to form PTV1 and CTV expanding 6mm to form PTV2. The dose of PTV1 is 50Gy/25 times for 35 days and the dose of PTV2 is 45Gy/25 times for 35 days. Patients were treated in consecutive days per week for a total of 5 weeks.
Study NCT01041183 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral ramosetron
Description: 0.1 mg oral ramosetron (group II)
Study NCT01041183 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral and IV ramosetron
Description: 0.1 mg oral ramosetron plus 0.3 mg IV ramosetron (group III).
Study NCT02834650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac MRI with contrast
Description: Cardiac MRI
Study NCT03671252 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Description: Chemotherapy: oral capecitabine（1650 mg/m2）twice daily during radiotherapy without weekend breaks.~Radiation: Radiation therapy is administered via intensity-modulated radiation therapy (IMRT) with a linear accelerator, 6MV-X ray. The patients are scheduled to receive a GTV expanding 6mm to form PTV1 and CTV expanding 6mm to form PTV2. The dose of PTV1 is 50Gy/25 times for 35 days and the dose of PTV2 is 45Gy/25 times for 35 days. Patients were treated in consecutive days per week for a total of 5 weeks.
Study NCT03671252 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TME operation
Description: TME operation
Study NCT02615418 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIBS system for evaluation and treatment utilizing non invasive brain stimulation
Study NCT02615418 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: NIBS system for evaluation and treatment utilizing non invasive brain stimulation
Study NCT01882387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TXA127
Description: Injection, 300mcg/kg/day for 28 days
Study NCT04573790 — intervention group
Intervention type: PROCEDURE
Intervention: eFONA
Description: Surgical Tracheotomy
Study NCT02063984 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Outpatient Treatment (IOP) + Contingency Management (CM)
Description: Multiple group sessions weekly, one individual counseling session weekly with teen to review and discuss contingency management abstinence-based incentives
Study NCT02063984 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Outpatient Treatment (IOP) + Contingency Management (CM)
Description: Multiple group sessions weekly, one individual counseling session weekly with teen to review and discuss contingency management abstinence-based incentives
Study NCT02063984 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working Memory Training
Description: 25 computer-delivered sessions of neurocognitive training
Study NCT00945373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcium dobesilate
Description: 2.5% gel
Study NCT04018703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: loading dose 30-50ug/kg followed by continuous infusion 10-30ug/kg/h
Study NCT02521740 — intervention group
Intervention type: OTHER
Intervention: Research questionnaires, blood sample
Description: assessment of health (frailty, nutrition, physical performance, depression, burden, sense of coherence, caregiver reaction)
Study NCT00973622 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation (rTMS) 10 Hertz (Hz)
Description: All participants will receive 90 10-pulse trains of 1 sec duration with an interval of 20 seconds. Smokers will receive the treatment twice, once in a nicotine-satiated condition, and once in a nicotine-withdrawal condition.
Study NCT00973622 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation (rTMS) 20Hz
Description: All participants will receive 45 20-pulse trains of 1 second duration with an interval of 20 seconds. Smokers will receive the treatment twice, once in a nicotine-satiated condition, and once in a nicotine-withdrawal condition.
Study NCT00973622 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SHAM repetitive transcranial magnetic stimulation (rTMS)
Description: The look and sound of active rTMS is reproduced with the same coil used in the active conditions. The magnetic field in the sham coil is markedly attenuated at only 5% of stimulator output. The feel of active stimulation will be reproduced by delivering monophasic current pulses to the left, frontalis muscle with a Isolated Stimulator and two carbon rubber electrodes. Smokers will receive Sham rTMS in both the nicotine-satiated and nicotine-withdrawal conditions.
Study NCT01937481 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Food Friends
Description: The Food Friends is a research-based preschool program designed to address childhood obesity by establishing healthful eating and physical activity behaviors in preschool-aged children. The Food Friends: Fun With New Foods (12 weeks) focuses on helping children increasing children's willingness to try new foods and The Food Friends: Get Movin' With Mighty Moves (18 weeks) aims to enhance preschoolers' gross motor skill development. In effort to sustain the preschool behavior changes, the messages from The Food Friends® (Super Taster and Mighty Mover) will be extended into early elementary school through a 'booster' program. The booster program will consist of a kindergarten and 1st grade curriculum with 5 monthly units.
Study NCT01610206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Patients will receive gemcitabine 1000 mg/m2 administered weekly on days 1 and 8 (30 minutes IV infusion) of each cycle for up to 6 cycles. Each cycle is 21 days.
Study NCT01610206 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Patients will receive gemcitabine 1000 mg/m2 administered weekly on days 1 and 8 (30 minutes IV infusion) of each cycle for up to 6 cycles. Each cycle is 21 days.
Study NCT01610206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: Patients will receive pazopanib 800mg PO daily on days 1-21 of treatment cycles
Study NCT00945373 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulsed dye laser
Description: All study patients will be treated with 595 nm PDL (Vbeam, Candela Corp, Wayland, Mass) with an initial test spot using a fluence of 10 J/cm2, 7-mm spot size and 1.5-ms pulse duration. Based on the biologic response of the test area, the fluence will accordingly be adjusted up or down to find a fluence that produces a transient purpuric effect for a few seconds only.
Study NCT02413476 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic-assisted Gastrectomy(RAG)
Description: Surgical procedure will be performed with da vinci Surgical System.The type of reconstruction will be selected according to the surgeon's experience.
Study NCT02413476 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic-assisted Gastrectomy(LAG)
Description: Surgical procedure will be performed with laparoscopic techniques.The type of reconstruction will be selected according to the surgeon's experience.
Study NCT01527877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: Patients will be instructed to take BKM120 orally at a dose of 100 mg with a glass of water once daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day. The patient will be dosed on a flat scale of mg/day and not be adjusted to body weight or body surface area. If vomiting occurs no attempt should be made to replace the dose.~• BKM120 should be taken 1-hour following a light meal. Please note that patients must avoid consumption of Seville orange (and juice), grapefruit or grapefruit juice, grapefruit hybrids, pummelos and exotic citrus fruits from 7 days prior to the first dose of study drug and during the entire study treatment period due to potential CYP3A4 interaction. Regular orange juice is allowed.
Study NCT03019757 — intervention group
Intervention type: RADIATION
Intervention: DaTscan
Description: A functional imaging of the dopamine transporter using the radioligand \[123I\]FP-CIT
Study NCT03019757 — intervention group
Intervention type: RADIATION
Intervention: F18-AV-45
Description: A brain scan to to measure the extent of amyloid deposition
Study NCT03019757 — intervention group
Intervention type: RADIATION
Intervention: FDG-PET
Description: a brain scan measuring total and regional cerebral glucose metabolism wtih positron emission tomographs with 2-(18F)
Study NCT03019757 — intervention group
Intervention type: GENETIC
Intervention: APOE genotype
Description: 10 ml of whole blood will be drawn and shipped to Athena Diagnostics for genetic testing.
Study NCT03019757 — intervention group
Intervention type: PROCEDURE
Intervention: Polysomnogram
Description: Overnight sleep study
Study NCT01148693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: gentamicin
Description: 10mg per 10ml of contrast media
Study NCT03019757 — intervention group
Intervention type: BEHAVIORAL
Intervention: Clinical Assessment
Description: Clinical assessments include cognitive, behavioral, and motor evaluations
Study NCT00133263 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary Bereavement Care
Description: a standardized bereavement intervention in Primary Care
Study NCT00133263 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: the current bereavement care in primary care
Description: the non-standardized bereavement care that usually provided family physicians in primary care
Study NCT01148693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gentamicin
Description: 10mg per 10ml of contrast media
Study NCT00648258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valdecoxib
Description: valdecoxib 10 mg tablet by mouth once daily for 6 weeks
Study NCT00648258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naproxen
Description: naproxen 500 mg capsule by mouth twice daily for 6 weeks
Study NCT02474303 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Truvada
Description: Demonstration Study
Study NCT03392428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA617
Description: Patients randomised to the 177Lu-PSMA617 arm will receive 6-8.5GBq of 177Lu-PSMA617 by intravenous injection once every 6 weeks until progressive disease, prohibitive toxicity or a maximum of 6 cycles.~The first dose will be administered at 8.5GBq, reducing by 0.5GBq with every cycle given (i.e. to 6.0GBq on the sixth cycle, if reached). In some patients who have an exceptional response, treatment will be paused but can be re-commenced up to the maximum of 6 cycles upon progression.
Study NCT03392428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabazitaxel
Description: Patients randomised to the Cabazitaxel arm will receive 20mg/m2 Cabazitaxel by intravenous infusion once every 3 weeks until progressive disease, prohibitive toxicity or a maximum of 10 cycles.~Patients in this arm will also receive prednisolone 10mg orally per day for the duration of their cabazitaxel treatment.
Study NCT03497039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Diethylamine (DDEA) gel
Description: Diclofenac Diethylamine (DDEA) gel consists of 2.32% DDEA. DDEA gel will be applied twice a day for 7 days topically first and last dose by trained nurse (or designee) at study site and doses in between by a trained nurse at participant's home or other convenient location. Participants will be admitted on the day before the scheduled surgery (Day 7). The last dose of study treatment will be administered at the study site 12 hours (window -1/+3 hrs) prior to arthroplasty surgery.If surgery is delayed by up to 7 days dosing with DDEA gel twice daily can continue up to 14 days. If the surgery is delayed by more than 7 days, the participant should be withdrawn from the study.
Study NCT03497039 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Placebo gel will be applied twice a day for 7 days topically first and last dose by trained nurse (or designee) at study site and doses in between by a trained nurse at participant's home or other convenient location. Participants will be admitted on the day before the scheduled surgery (Day 7). The last dose of placebo gel will be administered at the study site 12 hours (window -1/+3 hrs) prior to arthroplasty surgery. If surgery is delayed by up to 7 days dosing with placebo gel twice daily can continue up to 14 days. If the surgery is delayed by more than 7 days, the participant should be withdrawn from the study.
Study NCT04140786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin Sulfate, Injectable
Description: 10mg/kg prepared from commercially available stock (typically Kabi Pharmaceuticals) by licensed pharmacists.
Study NCT01818843 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inhaled Carbon Monoxide
Description: Inhaled Carbon Monoxide in newborn
Study NCT05859646 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic use
Description: Probiotics were used for 3 months and all participated patients were followed for 6 months.
Study NCT00858351 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thermal Biofeedback Assisted Relaxation
Description: 6 sessions, 25 minutes in duration of relaxation and imagery training while temperature of hands and feet are recorded.
Study NCT00858351 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Discussion with therapist
Description: 6 sessions, 25 minutes each, discussing topics with a therapist.
Study NCT00778167 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cixutumumab
Description: Given IV
Study NCT00778167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO
Study NCT00778167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01446887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: prophylactic anticoagulation
Description: prophylactic anticoagulation by rivaroxaban
Study NCT01541488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1021958
Description: tablet
Study NCT01541488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1021958
Description: drinking solution / tablet